help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vafiadis, P.
Right arrow Articles by Polychronakos, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vafiadis, P.
Right arrow Articles by Polychronakos, C.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 8 2933-2939
Copyright © 1998 by The Endocrine Society


Original Studies

Divergence between Genetic Determinants of IGF2 Transcription Levels in Leukocytes and of IDDM2-Encoded Susceptibility to Type 1 Diabetes1

Petros Vafiadis, Simon T. Bennett2, John A. Todd, Rosemarie Grabs and Constantin Polychronakos

McGill University-Montreal Children’s Hospital Research Institute and the Department of Pediatrics, Division of Endocrinology, McGill University (P.V., R.G., C.P.), Montreal, Quebec, Canada H3H 1P3; and the Wellcome Trust Center for Human Genetics, Nuffield Department of Surgery, University of Oxford (S.T.B., J.A.T.), Oxford, United Kingdom OX3 7BN

Address all correspondence and requests for reprints to: Constantin Polychronakos, M.D., F.R.C.P.(C), Montreal Children’s Hospital, 2300 Tupper Street, Montreal, Quebec, Canada H3H 1P3. E-mail: mc97{at}musica.mcgill.ca


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The IDDM2 susceptibility locus in type 1 diabetes corresponds to a variable number of tandem repeats (VNTR) upstream of the insulin (INS) and insulin-like growth factor 2 (IGF2) genes. Large VNTR alleles (class III) are dominantly protective, whereas small alleles (class I) are predisposing. IGF2 has been considered a prime candidate for mediating IDDM2-encoded susceptibility because of its proximity to the VNTR, mitogenic properties and parental effects at IDDM2 suggest the involvement of an imprinted gene. IGF2 is imprinted with exclusive expression of the paternal gene. However, there is polymorphic relaxation of IGF2 imprinting in leukocytes. VNTR allelic variation affecting either the extent of relaxation or transcription independent of parental origin might explain the IDDM2 effect. To test this, we compared IGF2 expression between chromosomes with a class III or I allele in leukocytes and stimulated lymphocytes. No significant difference was detected between the two classes. Furthermore, the (+) allele of an ApaI polymorphism in the 3'-untranslated region of IGF2 was associated with significantly higher IGF2 messenger ribonucleic acid levels than the (-) allele, but was not associated with type 1 diabetes. The absence of transcriptional effects in leukocytes on IGF2 by the VNTR, which is the disease-predisposing locus, and the presence of a strong association between IGF2 levels and ApaI, which is not associated with the disease, argue against IGF2 expression in leukocytes as the mediator of IDDM2-encoded susceptibility. Taken together, these results support studies suggesting that INS expression in the thymus is a primary target of the IDDM2 susceptibility locus.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
TYPE 1 diabetes is a complex disorder linked to more than genetic loci (1). Linkage and association studies have shown that one of these loci, IDDM2, maps to (2, 3, 4, 5, 6, 7) and has been identified as (8, 9) a variable number of tandem repeats (VNTR) minisatellite, 596 bp upstream of the insulin gene (INS) translational start site and about 4 kb upstream of the insulin-like growth factor 2 gene (IGF2). The VNTR is composed of a variable number of repeats of a 14- to 15-bp consensus sequence (ACAGGGGTGTGGGG) (5, 10, 11, 12, 13) (Fig. 1Go). Class I VNTR alleles (26–63 repeat units) predispose to type 1 diabetes, whereas class III VNTR alleles (140–210 repeat units) are dominantly protective (14). Within class III, there are two size modes identifiable by linkage disequilibrium with neighboring polymorphisms, one of which is more protective [very protective haplotype (VPH)] than the other [protective haplotype (PH)].



View larger version (19K):
[in this window]
[in a new window]
 
Figure 1. The IDDM2 susceptibility locus on chromosome 11p15.5, has been identified as the VNTR minisatellite upstream of INS and IGF2. The three INS exons and nine IGF2 exons are shown. The IGF2 ApaI 3' UTR RFLP is located in exon 9 (*) and is common to transcripts from all four (P1 to P4) promoters.

 
The VNTR is not transcribed; thus, its effect on type 1 diabetes susceptibility must involve control of gene expression levels. We have undertaken a systematic search for the susceptibility mechanism by evaluating transcriptional effects of VNTR alleles on two obvious candidate target genes, INS and IGF2, in pancreas and thymus, two tissues known to be of importance in the pathogenesis of type 1 diabetes (8, 14, 15, 16). We recently proposed an autoimmune mechanism by which class I and III VNTR alleles at the IDDM2 locus may differentially affect susceptibility based on tissue-specific VNTR allelic effects on INS messenger ribonucleic acid (mRNA) levels. The protective class III alleles are associated with markedly higher insulin levels in thymus than class I alleles (16, 17). The higher thymic insulin levels associated with the protective alleles may result in improved immune tolerance induction to INS translation products. As insulin is the only known ß-cell-specific autoantigen, this may decrease the probability of developing an autoimmune response to the insulin-producing pancreatic ß-cells.

A functional effect of VNTR alleles on INS does not preclude the possibility that other genes, such as IGF2, are also targets of the IDDM2 effect. It has been hypothesized that the IDDM2 target gene is IGF2 (18, 19). Several studies report parent of origin effects in the genetics of the IDDM2 locus (3, 8, 14, 20, 21, 22, 23). This suggests involvement of a gene subject to parental imprinting, the phenomenon by which a gene is expressed only or mostly from the gene copy inherited from the parent of a specific sex. IGF2 is an imprinted gene with exclusive expression from the paternal allele in most tissues (24). In leukocytes, there is a genotype-dependent variable relaxation of IGF2 imprinting (25), with expression of the maternal gene copy ranging from complete repression to expression equal to that of the paternal copy (15). This variable reactivation of the maternal allele in leukocytes could result in a biologic effect of maternal haplotypes on expression levels of IGF2. Depending on haplotype frequencies in different populations, such an effect could appear stronger or weaker than the paternal one in genetic studies of end-point biologic effects such as diabetes susceptibility.

A role for IGF2 in type 1 diabetes has also been proposed based on its biological properties as a mitogenic peptide, active in thymus, pancreas, and activated lymphocytes (reviewed in Ref. 19) and its potential role as a selecting peptide in the thymus, which may help induce immune tolerance to proinsulin, with which it shares significant homology (18, 26). In addition, there are less direct mechanisms by which IGF2 could affect susceptibility. For example, class I VNTR alleles are associated with somewhat increased IGF2 expression in placenta (27), which may affect intrauterine growth and birth size. Birth weight and early growth patterns were found to be associated with type 1 diabetes risk in some studies (28, 29, 30, 31).

The three tissues known to be critical to the pathogenesis of type 1 diabetes are thymus, where immune tolerance develops, pancreas, where the autoimmune assault occurs, and leukocytes, which mediate ß-cell destruction. Evaluation of the effects of VNTR on IGF mRNA levels in thymus and pancreas revealed no differential effect of VNTR allele class (32). We now focus on leukocytes.

T lymphocytes and their thymic precursors express both IGF-II and the type I IGF receptor (19, 33). Transgenic mice overexpressing IGF2 in the thymus under the class II MHC promoter had a large increase in T lymphocyte number (34, 35). The same effect could not be achieved by IGF-II administration, and despite plasma IGF-II levels that were 2–3 times higher in transgenic mice than in wild-type, only tissues expressing the IGF2 transgene had increased growth. Autocrine and paracrine signaling mechanisms play a major role in the biological action of the IGF-II peptide. Thus, alleles that increase IGF2 mRNA levels would increase local IGF-II levels and therefore increase the survival of lymphocytes and their resistance to apoptosis, including potentially autoreactive and activated lymphocytes. Such alleles would be predisposing to type 1 diabetes.

In this report, we present studies in leukocytes showing a divergence between genetic determinants of IGF2 expression in leukocytes, on the one hand, and diabetes, on the other; the VNTR allele classes determining diabetes susceptibility have no differential effects on IGF2 expression levels, whereas an ApaI restriction fragment length polymorphism (RFLP) in the 3'-untranslated region (3'-UTR) of IGF2, a polymorphism strongly associated with IGF2 expression levels, shows no association with type 1 diabetes.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Samples

Peripheral blood samples were obtained from type 1 diabetes patients and their parents from the Montreal Children’s Hospital diabetic clinic, with signed informed consent and approval by the institutional review board of the Montreal Children’s Hospital and the Quebec Ministry of Health. Nucleic acids were purified by phenol-chloroform extraction. Lymphocytes were separated by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) and stimulated with 5 mg/mL concanavalin A for 48 h before collection.

Genotyping

All samples were genotyped for VNTR status as described previously (8, 14, 15, 16). Class I alleles are designated by size in mobility units (8) or repeat number (36), following previously established terminology. Stable transmission of the VNTR alleles was confirmed by typing available parental DNA.

Amplification of a 236-bp segment of the IGF2 3'-UTR containing an ApaI RFLP common to transcripts from all four promoters was carried out as previously described (37). The [32P]deoxy-ATP internally labeled PCR product was digested with ApaI and electrophoresed in a polyacrylamide gel. Heterozygous samples were identified as those with a 236-bp undigested band and two digestion fragments of 173 and 63 bp. Complete digestion was ensured by the inclusion of a sample homozygous for the ApaI cutting site with all digest runs.

Linkage disequilibrium measurements

The extent of linkage disequilibrium in the Canadian-UK data set (n = 676) is described by the coefficient of linkage disequilibrium D' (38, 39) calculated as follows: D' = D/Dmax with D = pab - papb, where pab = frequency of haplotypes with allele a at one locus and allele b at another locus, pa = frequency of allele a, pb = frequency of allele b, and Dmax = pa(1 - pb) is the maximum linkage disequilibrium possible.

Quantitation of IGF2 in leukocytes and lymphocytes

We compared the relative expression levels of the two IGF2 gene copies within each sample, using a previously described method (15). Briefly, for VNTR and ApaI we determined the VNTR/ApaI haplotypes and their parental origin in the child. Individuals who were VNTR class I/III and ApaI +/- double heterozygotes, with haplotypes of known parental origin, were selected for further study. To distinguish the transcripts originating from each chromosome, RNA was reverse transcribed to complementary DNA, and the ApaI fragment was amplified by PCR. The PCR products, labeled internally with [32P]deoxy-ATP, were digested with ApaI, resolved by PAGE, and quantified using a phosphorimager (Fuji, Tokyo, Japan) to obtain a ratio of the 173-bp band representing the digested ApaI(+) allele to the 236-bp undigested band representing the ApaI(-) allele. The same procedure was performed for DNA, where the two alleles are known to be present in equal abundance. Each ratio shown is the average of two to seven separate measurements. If the two alleles are present in equal abundance, then the RNA ratio will equal the DNA ratio. Any differences between the two ratios represent a difference in the relative abundance of the mRNA of the two alleles. To control for the imprinting effect, the ratio of the paternal over maternal allele was compared as follows: RNA/DNA = [ApaI(+)/ApaI(-) RNA ratio]/[ApaI(+)/ApaI(-) DNA ratio] (Eq. 1). If ApaI(+) is the paternal allele, take the ratio from Eq. 1 as: RNA/DNA (Eq. 2A). If ApaI(-) is the paternal allele, take the ratio from Eq. 1 as: 1/(RNA/DNA) (Eq. 2B).

Absolute IGF2 mRNA levels in leukocytes were quantified using a quantitative competitive RT-PCR method described in detail previously (32). Each subject was assayed from one to three separate blood samples drawn on different days. Each sample was assayed using one to four different competitor concentrations. Some samples were assayed in duplicate using the same RNA sample in two different RT reactions and assaying both reactions in parallel. As both IGF2 alleles are expressed in this tissue, the absolute quantitation represents the sum of the transcripts from both alleles. From the ratio of paternal/maternal allele levels in each RNA sample, we were then able to calculate which fraction of the total IGF2 mRNA came from the chromosome inherited from each parent.

mRNA stability study

To determine whether the effect of the ApaI polymorphism on IGF2 mRNA levels is due to differential RNA stability, lymphocytes from an ApaI(±) individual known to equally express both copies of IGF2 were stimulated for 72 h with concanavalin A, followed by addition of the transcription blocker actinomycin D. The cells were collected at various time points, and RNA was extracted using Trizol (Life Technologies, Gaithersburg, MD). The ApaI fragment was amplified from RNA by RT-PCR and digested with ApaI, and a ratio of the ApaI(+) to the ApaI(-) allele was obtained at each time point by quantitation of each band using a phosphorimager.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
IGF2 expression levels in leukocytes and lymphocytes

In leukocytes, there is a variable relaxation of IGF2 imprinting between individuals, ranging from complete repression of the maternal gene copy to equal expression of both copies (15). We have shown preliminary evidence that the VNTR is not the locus controlling the variable expression level of the maternal allele in leukocytes (15). However, the VNTR could modulate IGF2 expression independently of parental origin. Using an IGF2 3'-UTR ApaI RFLP to distinguish between alleles, the relative expressions of the paternal to maternal IGF2 gene copies were compared between individuals with a paternal class III-maternal class I VNTR status and those with a paternal class I-maternal class III status. The ratio of paternal to maternal IGF2 mRNA was not significantly different between these two groups [4.2 ± 1.5 (n = 4) vs. 3.1 ± 1.3 (n = 4)] in leukocytes (Fig. 2Go and Table 1Go), indicating that class III alleles do not affect IGF2 expression levels differently from class I alleles.



View larger version (47K):
[in this window]
[in a new window]
 
Figure 2. A, ApaI digestion of PCR products amplified from DNA and RNA in three ApaI(±) individuals. IGF2 imprinting in leukocytes is polymorphic, ranging from almost complete repression of the maternal gene copy (first and third panels) to equal expression of both copies (second panel), independently of which allele, (+) or (-), is maternal. B, A representative autoradiogram of the IGF2 mRNA quantitation in leukocyte samples by competitive RT-PCR is shown. To an equal amount of RNA, 0.0039 (a), 0.0078 (b), 0.0156 (c), and 0.0625 (d) attomoles of IGF2 PCR competitor were added. With increasing amounts of competitor template in the reaction (a to d), the amount of endogenous IGF2 PCR product relative to the amount of competitor decreases.

 

View this table:
[in this window]
[in a new window]
 
Table 1. The paternal and maternal VNTR/ApaI haplotypes for type 1 diabetes patients are shown, along with the relative expression level of the paternal to maternal IGF2 alleles in leukocytes and in stimulated lymphocytes

 
However, there is a striking association between the ApaI(+) allele and high IGF2 mRNA levels. The ratio of paternal to maternal IGF2 mRNA levels in these two groups ranges from 2.9–7.8 (mean, 5.3) where the paternal allele is ApaI(+), and only 0.5–1.3 (mean, 0.9) where the paternal allele is ApaI(-) (Table 1Go). To confirm this association, we compared the paternal to maternal IGF2 ratios in the larger dataset consisting of ApaI(±) heterozygous and VNTR class I/I individuals (Table 1Go). Once again the paternal to maternal ratio was higher with a paternal ApaI(+) than with a paternal ApaI(-) [mean, 7.9 (n = 13) vs. 0.6 (n = 10), respectively]. In samples with a paternal/maternal ratio significantly less than 1, the ApaI effect obviously overrides the parental imprinting effect.

Because of recent evidence that, unlike all other class I alleles, the allele designated 814 is not predisposing to diabetes when inherited from 814/III heterozygous fathers (23), we examined such alleles specifically. Of the 22 paternal alleles, only 2 were 814 that were inherited from 814 class III fathers. Neither could be distinguished from the rest of the class I alleles, either by ApaI haplotype (both were + as most 814 are) or by paternal/maternal ratio (4.0 and 5.5, values close to the median for ApaI heterozygotes with a paternal +). This may be taken as additional evidence that IGF2 levels in leukocytes are not relevant to the IDDM2 effect.

The class I VNTR alleles can be subdivided into a large and a small mode based on size and linkage disequilibrium with neighboring polymorphisms (38). Two hundred and seventy-six of 348 class I/ApaI(-) haplotypes analyzed contained a small class I allele (smaller than or equal to the 742 allele, 37 repeat units), and 970 of 1034 class I/ApaI(+) haplotypes had a large class I allele (larger than or equal to the 756 allele, 38 repeat units). Interestingly, only about 50% of the 728 and 742 class I alleles are in cis with ApaI(-), indicating that these 2 alleles are in linkage equilibrium with ApaI. Overall, the ApaI(-) allele is in strong linkage disequilibrium with small class I alleles (up to allele 714), whereas ApaI(+) is in strong linkage disequilibrium with large class I alleles (greater than allele 756, inclusive; D' = 0.82; Fig. 3Go). This suggested the possibility that ApaI could be a marker for a transcriptional effect of VNTR class I allele subgroups. When we examined mismatched haplotypes containing the ApaI(+) allele with a short class I VNTR or ApaI(-) with a long class I, the ApaI(+) allele was still expressed more strongly than the (-) allele, suggesting that the effect on IGF2 mRNA levels does not functionally reside in differential effects of the two class I size categories. Linkage disequilibrium of ApaI was also seen with the VPH class III alleles, as 15 of 18 VPH class III alleles analyzed were in cis with an ApaI(+) allele.



View larger version (16K):
[in this window]
[in a new window]
 
Figure 3. Linkage disequilibrium between an ApaI RFLP in the 3'-UTR of IGF2 and alleles of the upstream VNTR minisatellite. The open bars represent the ApaI(-) alleles, whereas the solid bars represent the ApaI(+) allele. Class I VNTR alleles are designated with a three-digit number (8 ).

 
We next determined whether our findings in leukocytes held true for stimulated lymphocytes. The same association of ApaI with IGF2 mRNA levels was confirmed in a subset of samples from which stimulated lymphocytes could be obtained [paternal ApaI(+) ratios between 1.2–2.7 (n = 4) vs. paternal ApaI(-) ratios between 0.4–1.0 (n = 5); Table 1Go]. There was a significant correlation between those ratios in leukocytes and stimulated lymphocytes from the same individual (r = 0.71).

Differential mRNA stability

Association of ApaI(+) alleles with higher IGF2 steady state mRNA levels than ApaI(-) may be a transcriptional effect, or it may indicate a difference in stability between the two transcripts. To investigate this, we arrested transcription in cultured lymphocytes using actinomycin D and compared the relative abundance of the two transcripts at various time points. The ratio of one allele to the other did not change significantly over this time period (Fig. 4Go); thus, the two alleles are equally stable under these conditions. This result indicates that both alleles have the unusually high stability of IGF2 mRNA reported by Sussenbach et al. (40), making it unlikely that the ApaI effect is due to differential RNA degradation.



View larger version (39K):
[in this window]
[in a new window]
 
Figure 4. Transcription in stimulated lymphocytes from an ApaI(±) individual who normally expresses both gene copies at an approximately equal level was blocked with actinomycin D. The relative abundance of the two alleles was measured at various times after blocking transcription and did not change significantly.

 
Paternal-maternal contributions to IGF2 mRNA levels

As ApaI does not affect mRNA stability, the only other explanation for the observed association between ApaI and IGF2 mRNA levels is that ApaI is associated with a transcriptional effect on IGF2. We hypothesized that the role of ApaI or, more likely, the sequence variant for which it is a marker is to act as an imprinting modifier locus that affects the extent to which the repressed maternal gene copy is activated, as imprinting of IGF2 has been shown to be genotype dependent (25). To determine whether parental origin affected the ApaI association with IGF2 mRNA levels, we used quantitative competitive RT-PCR to quantitate absolute levels of IGF2 mRNA in the samples for which the paternal to maternal ratio was known (Fig. 2Go). Combining the two, we determined the paternal and maternal contributions to the absolute amount of IGF2 mRNA. The maternal ApaI(+) IGF2 mRNA level (mean, 8.9 arbitrary units; n = 10) was still higher than the maternal ApaI(-) level (mean, 3.4; n = 14), and the paternal ApaI(+) mRNA level (mean, 17.0; n = 14) was higher than the paternal ApaI(-) level (mean, 4.4; n = 10; Table 1Go). Thus, the ApaI(+) allele is associated with higher IGF2 mRNA levels regardless of parental origin, indicating that the transcriptional effect does not involve modifying the extent to which imprinting is relaxed.

VNTR/ApaI genetic analysis

If genetic variation in IGF2 expression levels in leukocytes has a functional role in the development of type 1 diabetes, then the association of ApaI alleles with very different IGF2 mRNA levels would make ApaI a marker for diabetes susceptibility, either through linkage disequilibrium with specific VNTR alleles or independently of the VNTR. To investigate this possibility, we compared the number of transmitted to nontransmitted ApaI(+) and ApaI(-) alleles to diabetic children from unaffected parents. There was no significant difference in the frequency with which the alleles were transmitted to diabetic offspring from ApaI(±) heterozygous fathers or mothers, indicating the absence of an association between ApaI and type 1 diabetes (Table 2Go), and, consequently, no evidence for an association between ApaI RFLP-regulated IGF2 expression in leukocytes and type 1 diabetes.


View this table:
[in this window]
[in a new window]
 
Table 2. ApaI (-) and (+) alleles transmitted from ApaI heterozygous parents to diabetic offspring

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
To elucidate the IDDM2 mechanism in type 1 diabetes pathogenesis, we have evaluated the relationship between INS VNTR alleles and IGF2 expression in leukocytes. The protective class III alleles are associated with higher thymic insulin levels than class I alleles, suggesting a role for IDDM2 in establishing immune tolerance to INS translation products (16, 17). Alternatively, there is genetic and biological evidence suggesting that IDDM2 effects could be mediated through the nearby IGF2 gene. In human placenta we found that IGF2 mRNA derived from chromosomes with class I alleles was approximately 50% higher that from class III (27). No such effects were detected in thymus and pancreas, tissues known to be important to the pathogenesis of the disease (32). In this report we examine another critical tissue, leukocytes and stimulated lymphocytes. Our data in these cells clearly show no substantial difference in IGF2 mRNA levels transcribed from chromosomes with predisposing class I compared with protective class III VNTR alleles. Conversely, we found that the ApaI RFLP, the alleles of which were associated with a marked effect on IGF2 mRNA levels in these cells, was not associated with type 1 diabetes. This makes the reasonable assumption that the two alleles, which differ in the identity of only a single nucleotide, are reverse transcribed with equal efficiency. Thus, modulation of IGF2 mRNA levels in leukocytes does not make a significant contribution to type 1 diabetes susceptibility.

Despite its lack of association with diabetes, the ability of the ApaI polymorphism or a polymorphism in tight linkage disequilibrium with it to modulate IGF2 mRNA levels may be important in other human diseases, such as cancer and growth disorders in early life. The mechanism of this effect may involve either differential mRNA stability or effects on transcription levels of the gene. Our finding that blocking transcription had no effect on the ratio of the two alleles over time is evidence against differential RNA degradation as the mechanism of the ApaI effect. We also explored the possibility that the ApaI polymorphism was responsible for modifying the derepression of maternal gene expression. The ApaI(+) allele was associated with higher IGF2 mRNA levels regardless of parental origin, ruling out the possibility that ApaI or something in linkage disequilibrium with it acts as a modifier locus for IGF2 imprinting.

Alleles within each VNTR class are heterogeneous in terms of both size and sequence of variants of the consensus repeat unit (9). Although the majority of the reported contribution of the VNTR to the genetics of type 1 diabetes is between class I and class III as a whole, there is evidence that alleles within classes may differ in the degree of diabetes susceptibility or protection that they confer (8, 23). Therefore, although the main IDDM2 effect (class I vs. class III) cannot be accounted for by IGF2 modulation in the tissues examined, we cannot rule out that such modulation may play a role in the differences between alleles of the same class. Specifically, the ApaI effect could be due to an as yet unknown linkage disequilibrium with specific VNTR alleles.

We have demonstrated an absence of association between the VNTR locus responsible for the IDDM2 effect on susceptibility and expression levels of the nearby IGF2 gene in leukocytes, suggesting that IGF2 expression in leukocytes does not play a role in the autoimmune pathogenesis of type 1 diabetes. However, it is still possible that IGF2 modulation by the VNTR in other tissues, such as the small effect seen in placenta, could affect diabetes susceptibility through nonimmune mechanisms, such as influencing early growth patterns. The demonstration of the absence of modulation of IGF2 in tissues with the most obvious relevance to the immunology of type 1 diabetes weakens the position of IGF2 as a candidate target and reinforces the hypothesis that INS expression in the thymus is a primary mode of action of INS VNTR allelic variation in type 1 diabetes pathogenesis.


    Acknowledgments
 
We thank Ms. Jacqueline Dufresne, R.N., for assistance in recruitment of participating families and collection of blood samples.


    Footnotes
 
1 This work was supported by grants from the Juvenile Diabetes Foundation International and the Medical Research Council of Canada. P.V. is supported by a Doctoral Research Award from the Medical Research Council of Canada. Back

2 Present address: Oxagen Ltd., 91 Milton Park, Abingdon, Oxon, United Kingdom OX14 4RY. Back

Received March 11, 1998.

Accepted May 7, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Todd JA, Farrall M. 1994 Panning for gold: genome-wide scanning for linkage in type 1 diabetes. Hum Mol Genet. 5:1443–1448.[Abstract]
  2. Bell GI, Horita S, Karam JH. 1984 A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes. 33:176–183.[Abstract]
  3. Julier C, Hyer RN, Davies J, et al. 1991 Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. Nature. 354:155–159.[CrossRef][Medline]
  4. Lucassen AM, Julier C, Beressi JP, et al. 1993 Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nat Genet. 4:305–10.[CrossRef][Medline]
  5. Owerbach D, Gabbay KH. 1993 Localization of a type I diabetes susceptibility locus to the variable tandem repeat region flanking the insulin gene. Diabetes. 42:1708–1714.[Abstract]
  6. Julier C, Lucassen A, Villedieu P, et al. 1994 Multiple DNA variant association analysis: application to the insulin gene region in type I diabetes. Am J Hum Genet. 55:1247–1254.[Medline]
  7. Undlien DE, Bennett ST, Todd JA, et al. 1995 Insulin gene region-encoded susceptibility to IDDM maps upstream of the insulin gene. Diabetes. 44:620–625.[Abstract]
  8. Bennett ST, Lucassen AM, Gough SC, et al. 1995 Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet. 9:284–292.[CrossRef][Medline]
  9. Bennett ST, Todd JA. 1996 Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet. 30:343–370.[CrossRef][Medline]
  10. Bell GI, Selby MJ, Rutter WJ. 1982 The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. Nature. 295:31–35.[CrossRef][Medline]
  11. Ullrich A, Dull TJ, Gray A, Philips JA 3d, Peter S. 1982 Variation in the sequence and modification state of the human insulin gene flanking regions. Nucleic Acids Res. 10:2225–2240.[Abstract/Free Full Text]
  12. Owerbach D, Aagaard L. 1984 Analysis of a 1963-bp polymorphic region flanking the human insulin gene. Gene. 32:475–479.[CrossRef][Medline]
  13. Rotwein P, Yokoyama S, Didier DK, Chirgwin JM. 1986 Genetic analysis of the hypervariable region flanking the human insulin gene. Am J Hum Genet. 39:291–299.[Medline]
  14. Bennett ST, Wilson AJ, Cucca F, et al. 1996 IDDM2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. J Autoimm. 9:415–421.
  15. Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG, Polychronakos C. 1996 Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leucocytes. J Autoimmun. 9:397–403.[CrossRef][Medline]
  16. Vafiadis P, Bennett ST, Todd JA, et al. 1997 Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 susceptibility locus. Nat Genet. 15:289–292.[CrossRef][Medline]
  17. Pugliese A, Zeller M, Fernandez A Jr, et al. 1997 The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet. 15:293–297.[CrossRef][Medline]
  18. Geenen V, Achour I, Robert F, et al. 1993 Evidence that insulin-like growth factor 2 (IGF2) is the dominant thymic peptide of the insulin superfamily. Thymus. 21:115–127.[Medline]
  19. Polychronakos C, Giannoukakis N, Deal CL. 1995 Imprinting of IGF2, insulin-dependent diabetes, immune function, and apoptosis: a hypothesis. Dev Genet. 17:253–262.[CrossRef][Medline]
  20. Bui MM, Luo DF, She JY, et al. 1996 Paternally transmitted IDDM2 influences diabetes susceptibility despite biallelic expression of the insulin gene in human pancreas. J Autoimm. 9:97–103.
  21. Pugliese A, Awdeh ZL, Alper CA, Jackson RA, Eisenbarth GS. 1994 The paternally inherited insulin gene B allele (1,428 FokI site) confers protection from insulin-dependent diabetes in families. J Autoimm. 7:687–694.
  22. Polychronakos C, Kukuvitis A, Giannoukakis N, Colle E. 1995 Parental imprinting effect at the INS-IGF2 diabetes susceptibility locus. Diabetologia. 38:715–719.[Medline]
  23. Bennett ST, Wilson AJ, Esposito L, et al. 1997 Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. Nat Genet. 17:350–352.[CrossRef][Medline]
  24. Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C. 1993 Parental genomic imprinting of the human IGF2 gene. Nat Genet. 4:98–101.[CrossRef][Medline]
  25. Giannoukakis N, Deal C, Paquette J, Kukuvitis A, Polychronakos C. 1996 Polymorphic functional imprinting of the human IGF2 gene among individuals, in blood cells, is associated with H19 expression. Biochem Biophys Res Commun. 220:1014–1019.[CrossRef][Medline]
  26. Martens H, Goxe B, Geenen V. 1996 The thymic repertoire of neuroendocrine self-antigens: physiological implications in T-cell life and death. Immunol Today. 17:312–317.[CrossRef][Medline]
  27. Paquette J, Giannoukakis N, Polychronakos C, Vafiadis P, Deal C. 1998 The INS 5' variable number of tandem repeats is associated with IGF2 expression in humans. J Biol Chem. 273:14158–14164.[Abstract/Free Full Text]
  28. Dorner G, Thoelke H, Mohnike A, Schneider H. 1985 High food supply in perinatal life appears to favour the development of insulin-treated diabetes mellitus (ITDM) in later life. Exp Clin Endocrinol. 85:1–6.[Medline]
  29. Blom L, Persson LA, Dahlquist G. 1992 A high linear growth is associated with an increased risk of childhood diabetes mellitus. Diabetologia. 35:528–533.[CrossRef][Medline]
  30. Johansson C, Samuelsson U, Ludvigsson J. 1994 A high weight gain early in life is associated with an increased risk of type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 37:91–94.[Medline]
  31. Dahlquist G, Bennich SS, Kallen B. 1996 Intrauterine growth pattern and risk of childhood onset insulin dependent (type I) diabetes: population based case-control study. Br Med J. 13:1174–1177.
  32. Vafiadis P, Grabs R, Goodyer CG, Colle E, Polychronakos C. 1998 A functional analysis of the role of IGF2 in IDDM2 ecoded susceptibility to type 1 diabetes. Diabetes. 47:831–836.[Abstract]
  33. Kooijman R. Scholtens LE. Rijkers GT. Zegers BJ. 1995 Type I insulin-like growth factor receptor expression in different developmental stages of human thymocytes. J Endocrinol. 147:203–209.[Abstract/Free Full Text]
  34. van Buul-Offers SC, de Haan K, Reijnen-Gresnigt MG, et al. 1995 Overexpression of human insulin-like growth factor-II in transgenic mice causes increased growth of the thymus. J Endocrinol. 144:491–502.[Abstract/Free Full Text]
  35. Kooijman R, van Buul-Offers SC, Scholtens LE, et al. 1995 T cell development in insulin-like growth factor-II transgenic mice. J Immunol. 154:5736–5745.[Abstract]
  36. McGinnis RE, Spielman RS. 1995 Insulin gene 5' flanking polymorphism. Length of class 1 alleles in number of repeat units. Diabetes. 44:1296–1302.[Abstract]
  37. Tadokoro K, Fujii H, Inoue T, Yamada M. 1991 Polymerase chain reaction (PCR) for detection of ApaI polymorphism at the insulin like growth factor II gene (IGF2). Nucleic Acids Res. 19:6967.[Free Full Text]
  38. McGinnis RE, Spielman RS. 1994 Linkage disequilibrium in the insulin gene region: size variation at the 5' flanking polymorphism and bimodality among "class I" alleles. Am J Hum Genet. 55:526–32.[Medline]
  39. Lewontin RC. 1964 The interaction of selection and linkage. I. General considerations: heterotic models. Genetics. 49:49–67.[Free Full Text]
  40. Sussenbach JS, Steenbergh PH, Jansen E, et al. 1991 Structural and regulatory aspects of the human genes encoding IGF-I and -II. Adv Exp Med Biol. 293:1–14.



This article has been cited by other articles:


Home page
Am. J. PsychiatryHome page
R. Bachner-Melman, A. H. Zohar, L. Nemanov, U. Heresco-Levy, I. Gritsenko, and R. P. Ebstein
Association Between the Insulin-Like Growth Factor 2 Gene (IGF2) and Scores on the Eating Attitudes Test in Nonclinical Subjects: A Family-Based Study
Am J Psychiatry, December 1, 2005; 162(12): 2256 - 2262.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
I. Durinovic-Bello, E. Jelinek, M. Schlosser, T. Eiermann, B. O. Boehm, W. Karges, L. Marchand, and C. Polychronakos
Class III Alleles at the Insulin VNTR Polymorphism Are Associated With Regulatory T-Cell Responses to Proinsulin Epitopes in HLA-DR4, DQ8 Individuals
Diabetes, December 1, 2005; 54(suppl_2): S18 - S24.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. S. Sandhu, B. Heude, E. H. Young, R. Luben, J. Luan, K.-T. Khaw, J. Todd, and N. J. Wareham
INS VNTR Class Genotype and Indexes of Body Size and Obesity: Population-Based Studies of 7,999 Middle-Aged Men and Women
Diabetes, September 1, 2005; 54(9): 2812 - 2815.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. F. Escobar-Morreale, M. Luque-Ramirez, and J. L. San Millan
The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome
Endocr. Rev., April 1, 2005; 26(2): 251 - 282.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. A. Schrager, S. M. Roth, R. E. Ferrell, E. J. Metter, E. Russek-Cohen, N. A. Lynch, R. S. Lindle, and B. F. Hurley
Insulin-like growth factor-2 genotype, fat-free mass, and muscle performance across the adult life span
J Appl Physiol, December 1, 2004; 97(6): 2176 - 2183.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. A. McCann, Y. Q. Xu, R. Frechette, L. Guazzarotti, and C. Polychronakos
The Insulin-Like Growth Factor-II Receptor Gene Is Associated with Type 1 Diabetes: Evidence of a Maternal Effect
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5700 - 5706.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. L. San Millan, M. Corton, G. Villuendas, J. Sancho, B. Peral, and H. F. Escobar-Morreale
Association of the Polycystic Ovary Syndrome with Genomic Variants Related to Insulin Resistance, Type 2 Diabetes Mellitus, and Obesity
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2640 - 2646.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pathol.Home page
M A Kelly, M L Rayner, C H Mijovic, and A H Barnett
Molecular aspects of type 1 diabetes
Mol. Pathol., February 1, 2003; 56(1): 1 - 10.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vafiadis, P.
Right arrow Articles by Polychronakos, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vafiadis, P.
Right arrow Articles by Polychronakos, C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals